Abstract
Multiple new agents are currently being developed in chronic myelogenous leukemia (CML). Most of these agents are now being investigated in patients who have developed resistance to imatinib. Their mechanisms of action are diverse and many may be synergistic with imatinib. These agents will be used soon in different combinations, most likely including imatinib, with the hope of obtaining a complete blockade of the intracellular pathways that are triggered by Bcr-Abl. If this is successful, complete eradication of disease may become a reality for the majority of patients with CML.
| Original language | English |
|---|---|
| Pages (from-to) | 501-512 |
| Number of pages | 12 |
| Journal | JNCCN Journal of the National Comprehensive Cancer Network |
| Volume | 1 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1 Nov 2003 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Bcr-abl
- Chemotherapy
- Chronic myelogenous leukemia
- Imatinib
- Intracellular pathways
- New agents
Fingerprint
Dive into the research topics of 'New agents in chronic myelogenous leukemia'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver